Literatur
-
1
Nedeltchev K, de Maur T A, Georgiadis D et al.
Ischaemic stroke in young adults: predictors of outcome and recurrence.
J Neurol Neurosurg Psychiatry.
2005;
76
191-195
-
2
Bogousslavsky J, Pierre P.
Ischemic stroke in patients under age 45.
Neurol Clin.
1992;
10
113-124
-
3
Kraemer M, Linden D, Berlit P.
The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.
J Neurol.
2005;
252
1155-1166
-
4
Kittner S J, Stern B J, Wozniak M et al.
Cerebral infarction in young adults: the Baltimore-Washington Cooperative Young Stroke Study.
Neurology.
1998;
50
890-894
-
5
Reynolds H R, Tunick P A, Kronzon I.
Role of transesophageal echocardiography in the evaluation of patients with stroke.
Curr Opin Cardiol.
2003;
18
340-345
-
6
Nabavi D G, Allroggen A, Ringelstein E B.
[Juvenile ischemic brain infarction. Clinical aspects, etiology spectrum, diagnosis and therapy].
Nervenarzt.
2004;
75
167-186
-
7
Manabe H, Yonezawa K, Kato T et al.
Incidence of intracranial arterial dissection in non-emergency outpatients complaining of headache: preliminary investigation with MRI / MRA examinations.
Acta Neurochir Suppl.
2010;
107
41-44
-
8 Diener H C, Putzki N, Berlit P et al. Leitlinien für Diagnostik und Therapie in der Neurologie.. 4th ed. Stuttgart: Thieme; 2008
-
9
Lyrer P, Engelter S.
Antithrombotic drugs for carotid artery dissection.
Cochrane Database Syst Rev.
2000;
CD000255
-
10
Sheikh S I, Singhal A B.
Extension of „roller coaster dissection” after tissue plasminogen activator.
AJNR Am J Neuroradiol.
2010;
31
E4
-
11
Perdu J, Boutouyrie P, Lahlou-Laforet K et al.
[Vascular Ehlers-Danlos syndrome].
Presse Med.
2006;
35
1864-1875
-
12
Schievink W I.
Cerebrovascular Involvement in Ehlers-Danlos Syndrome.
Curr Treat Options Cardiovasc Med.
2004;
6
231-236
-
13
Schievink W I, Limburg M, Oorthuys J W et al.
Cerebrovascular disease in Ehlers-Danlos syndrome type IV.
Stroke.
1990;
21
626-632
-
14
Byers P H.
Ehlers-Danlos syndrome type IV: a genetic disorder in many guises.
J Invest Dermatol.
1995;
105
311-313
-
15
North K N, Whiteman D A, Pepin M G et al.
Cerebrovascular complications in Ehlers-Danlos syndrome type IV.
Ann Neurol.
1995;
38
960-964
-
16
Pepin M, Schwarze U, Superti-Furga A et al.
Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type.
N Engl J Med.
2000;
342
673-680
-
17
Schievink W I, Piepgras D G, Earnest F T et al.
Spontaneous carotid-cavernous fistulae in Ehlers-Danlos syndrome Type IV. Case report.
J Neurosurg.
1991;
74
991-998
-
18
Sandok B A.
Fibromuscular dysplasia of the internal carotid artery.
Neurol Clin.
1983;
1
17-26
-
19
Osborn A G, Anderson R E.
Angiographic spectrum of cervical and intracranial fibromuscular dysplasia.
Stroke.
1977;
8
617-626
-
20
Corrin L S, Sandok B A, Houser O W.
Cerebral ischemic events in patients with carotid artery fibromuscular dysplasia.
Arch Neurol.
1981;
38
616-618
-
21
Singhal A B.
Cerebral vasoconstriction syndromes.
Top Stroke Rehabil.
2004;
11
1-6
-
22
Kraemer M, Berlit P.
Reversibles zerebrales Vasokonstriktionssyndrom versus zerebrale Vaskulitis.
Der Nervenarzt.
2010;
epub ahead of print
-
23
Singhal A B.
Thunderclap headache, reversible cerebral arterial vasoconstriction, and unruptured aneurysms.
J Neurol Neurosurg Psychiatry.
2002;
73
96; author reply 96-97
-
24
Calabrese L H, Dodick D W, Schwedt T J et al.
Narrative review: reversible cerebral vasoconstriction syndromes.
Ann Intern Med.
2007;
146
34-44
-
25 Singhal A B, Koroshetz W R, Caplan L R. Reversible cerebral vasoconstriction syndromes.. 2. ed. Cambridge University Press; 2010
-
26
Singhal A B, Topcuoglu M A, Dorer D J et al.
SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage.
Neurology.
2005;
64
1008-1013
-
27
Rosenbloom M H, Singhal A B.
CT angiography and diffusion-perfusion MR imaging in a patient with ipsilateral reversible cerebral vasoconstriction after carotid endarterectomy.
AJNR Am J Neuroradiol.
2007;
28
920-922
-
28
Kraemer M, Berlit P.
Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases.
Rheumatol Int.
2009;
201
1471-1476
-
29
Kraemer M, Berlit P.
Primary central nervous system vasculitis: clinical experiences with 21 new European cases.
Rheumatol Int.
2009;
epub ahead of print
-
30
Salvarani C, Brown Jr R D, Calamia K T et al.
Primary central nervous system vasculitis: analysis of 101 patients.
Ann Neurol.
2007;
62
442-451
-
31
Zuber M, Blustajn J, Arquizan C et al.
Angiitis of the central nervous system.
J Neuroradiol.
1999;
26
101-117
-
32
Salvarani C, Brown Jr R D, Calamia K T et al.
Primary CNS vasculitis with spinal cord involvement.
Neurology.
2008;
70
2394-2400
-
33
Goertz C, Wegner C, Bruck W et al.
Primary angiitis of the CNS with pure spinal cord involvement: a case report.
J Neurol.
2010;
257
1762-1764
-
34
Berlit P.
Isolated angiitis of the CNS and bacterial endocarditis: similarities and differences.
J Neurol.
2009;
256
792-795
-
35
Sloan M A, Kittner S J, Feeser B R et al.
Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study.
Neurology.
1998;
50
1688-1693
-
36
Kraemer M, Berlit P.
Primary central nervous system vasculitis and moyamoya disease: similarities and differences.
J Neurol.
2010;
257
816-819
-
37
Calabrese L H, Molloy E S, Singhal A B.
Primary central nervous system vasculitis: progress and questions.
Ann Neurol.
2007;
62
430-432
-
38
Miller D H, Ormerod I E, Gibson A et al.
MR brain scanning in patients with vasculitis: differentiation from multiple sclerosis.
Neuroradiology.
1987;
29
226-231
-
39
Iancu-Gontard D, Oppenheim C, Touze E et al.
Evaluation of hyperintense vessels on FLAIR MRI for the diagnosis of multiple intracerebral arterial stenoses.
Stroke.
2003;
34
1886-1891
-
40
Kadkhodayan Y, Alreshaid A, Moran C J et al.
Primary angiitis of the central nervous system at conventional angiography.
Radiology.
2004;
233
878-882
-
41
Hellmann D B, Roubenoff R, Healy R A et al.
Central nervous system angiography: safety and predictors of a positive result in 125 consecutive patients evaluated for possible vasculitis.
J Rheumatol.
1992;
19
568-572
-
42
Moore P M.
Diagnosis and management of isolated angiitis of the central nervous system.
Neurology.
1989;
39
167-173
-
43
Calabrese L H, Duna G F.
Evaluation and treatment of central nervous system vasculitis.
Curr Opin Rheumatol.
1995;
7
37-44
-
44
Duna G F, Calabrese L H.
Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system.
J Rheumatol.
1995;
22
662-667
-
45
Berlit P.
Primary angiitis of the CNS – an enigma that needs world-wide efforts to be solved.
Eur J Neurol.
2009;
16
10-11
-
46
Aras R, da Matta J A, Mota G et al.
Cerebral infarction in autopsies of chagasic patients with heart failure.
Arq Bras Cardiol.
2003;
81
411-416
-
47
Tipping B, de Villiers L, Candy S et al.
Stroke caused by human immunodeficiency virus-associated intracranial large-vessel aneurysmal vasculopathy.
Arch Neurol.
2006;
63
1640-1642
-
48
Rabinstein A A.
Stroke in HIV-infected patients: a clinical perspective.
Cerebrovasc Dis.
2003;
15
37-44
-
49
Calabrese L H.
Vasculitis and infection with the human immunodeficiency virus.
Rheum Dis Clin North Am.
1991;
17
131-147
-
50
Danielsen A G, Weismann K, Jorgensen B B et al.
Incidence, clinical presentation and treatment of neurosyphilis in Denmark 1980–1997.
Acta Derm Venereol.
2004;
84
459-462
-
51 Fritz V U, Bryer A. Stroke in persons infected with HIV.. In: Caplan L R Uncommon causes of stroke.. Cambridge: Cambridge Medicine; 2008
-
52
Weyand C M, Goronzy J J.
Giant-cell arteritis and polymyalgia rheumatica.
Ann Intern Med.
2003;
139
505-515
-
53
Kraemer M, Metz A, Herold M et al.
Reduction in jaw opening: a neglected symptom of giant cell arteritis.
Rheumatol Int.
2010;
epub ahead of print
-
54
Hashimoto Y, Tanaka M, Hata A et al.
Four years follow-up study in patients with Takayasu arteritis and severe aortic regurgitation; assessment by echocardiography.
Int J Cardiol.
1996;
54
S173-176
-
55
Hata A, Noda M, Moriwaki R et al.
Angiographic findings of Takayasu arteritis: new classification.
Int J Cardiol.
1996;
54
S155-163
-
56
Berlit P.
[Cerebral vasculitis].
Nervenarzt.
2004;
75
817-828; quiz 829–830
-
57
Berlit P, Stueper B, Fink I et al.
Behcet’s disease is associated with increased concentrations of antibodies against phosphatidylserine and ribosomal phosphoproteins.
Vasa.
2005;
34
176-180
-
58
Kramer M, Baumgartel M W, Neuen-Jacob E et al.
[Myalgia in Neuro-Behcet’s disease. Medication side effects or expression of underlying disease].
Z Rheumatol.
2008;
67
232-236
-
59
Greenberg S M, Vonsattel J P, Stakes J W et al.
The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage.
Neurology.
1993;
43
2073-2079
-
60
Haan J, Bakker E, Jennekens-Schinkel A et al.
Progressive dementia, without cerebral hemorrhage, in a patient with hereditary cerebral amyloid angiopathy.
Clin Neurol Neurosurg.
1992;
94
317-318
-
61
Haan J, Roos R A.
Comparison between the Icelandic and Dutch forms of hereditary cerebral amyloid angiopathy.
Clin Neurol Neurosurg.
1992;
94
S82-83
-
62
Roos R A, Haan J.
Function of amyloid and amyloid protein precursor.
Clin Neurol Neurosurg.
1992;
94
S1-3
-
63
Berlit P.
The spectrum of vasculopathies in the differential diagnosis of vasculitis.
Semin Neurol.
1994;
14
370-379
-
64
Kramer M, Berlit P.
[Moyamoya disease – a rare vasculopathy in Europeans].
Fortschr Neurol Psychiatr.
2010;
78
542-550; quiz 551
-
65
Kraemer M, Heienbrok W, Berlit P.
Moyamoya disease in Europeans.
Stroke.
2008;
39
3193-3200
-
66
Earley C J, Kittner S J, Feeser B R et al.
Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study.
Neurology.
1998;
51
169-176
-
67
Wakai K, Tamakoshi A, Ikezaki K et al.
Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey.
Clin Neurol Neurosurg.
1997;
99
(S 02)
S1-5
-
68
Ikeda K, Iwasaki Y, Kashihara H et al.
Adult moyamoya disease in the asymptomatic Japanese population.
J Clin Neurosci.
2006;
13
334-338
-
69
Yonekawa Y, Ogata N, Kaku Y et al.
Moyamoya disease in Europe, past and present status.
Clin Neurol Neurosurg.
1997;
99
(S 02)
S58-60
-
70
Fukui M, Kono S, Sueishi K et al.
Moyamoya disease.
Neuropathology.
2000;
20
S61-64
-
71
Roder C, Nayak N R, Khan N et al.
Genetics of Moyamoya disease.
J Hum Genet.
2010;
55
711-716
-
72
Roder C, Peters V, Kasuya H et al.
Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans.
Childs Nerv Syst.
2010;
epub ahead of print
-
73
Roder C, Peters V, Kasuya H et al.
Analysis of ACTA2 in European Moyamoya disease patients.
Eur J Paediatr Neurol.
2010;
epub ahead of print
-
74
Roder C, Peters V, Kasuya H et al.
Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients.
Acta Neurochir (Wien).
2010;
152
2153-2160
-
75
Inoue T K, Ikezaki K, Sasazuki T et al.
Analysis of class II genes of human leukocyte antigen in patients with moyamoya disease.
Clin Neurol Neurosurg.
1997;
99
(S 02)
S234-237
-
76
Inoue T K, Ikezaki K, Sasazuki T et al.
DNA typing of HLA in the patients with moyamoya disease.
Jpn J Hum Genet.
1997;
42
507-515
-
77
Achrol A S, Guzman R, Lee M et al.
Pathophysiology and genetic factors in moyamoya disease.
Neurosurg Focus.
2009;
26
E4
-
78
Muroi C, Yonekawa Y, Khan N et al.
Metabolic changes after H(2) 15O-positron emission tomography with acetazolamide in a patient with moyamoya disease: case report and review of previous cases.
J Neurosurg Anesthesiol.
2003;
15
131-139
-
79
Weber B, Westera G, Treyer V et al.
Constant-infusion H(2)15O PET and acetazolamide challenge in the assessment of cerebral perfusion status.
J Nucl Med.
2004;
45
1344-1350
-
80
Khan N, Dodd R, Marks M P et al.
Failure of Primary Percutaneous Angioplasty and Stenting in the Prevention of Ischemia in Moyamoya Angiopathy.
Cerebrovasc Dis.
2010;
31
147-153
-
81
Wohlrab J, Fischer M, Marsch W C.
[Current diagnosis of Sneddon syndrome].
Dtsch Med Wochenschr.
2001;
126
725-728
-
82
Boesch S M, Plorer A L, Auer A J et al.
The natural course of Sneddon syndrome: clinical and magnetic resonance imaging findings in a prospective six year observation study.
J Neurol Neurosurg Psychiatry.
2003;
74
542-544
-
83
de Aquino Gondim F A, Leacock R O, Subrammanian T A et al.
Intracerebral hemorrhage associated with Sneddon’s syndrome: is ischemia-related angiogenesis the cause? Case report and review of the literature.
Neuroradiology.
2003;
45
368-372
-
84
Kraemer M, Berlit P.
Cerebral haemorrhage as the presenting form of Sneddon’s syndrome.
Clin Neurol Neurosurg.
2008;
110
533
-
85
Kraemer M, Baumgaertel M W, Berlit P.
Miscarriage, peripheral thromboses and aortic aneurysm in antiphospholipid-antibody-negative Sneddon’s syndrome.
J Neurol.
2007;
254
1599-1600
-
86
Kraemer M, Berlit P.
Long-term course of antiphospholipid-antibody-negative Sneddon’s syndrome.
Clin Neurol Neurosurg.
2008;
110
1072
-
87
Hachulla E, Piette A M, Hatron P Y et al.
[Aspirin and antiphospholipid syndrome].
Rev Med Interne.
2000;
21
(S 01)
83s-88s
-
88
Floel A, Imai T, Lohmann H et al.
Therapy of Sneddon syndrome.
Eur Neurol.
2002;
48
126-132
-
89
Frances C, Piette J C.
The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus.
J Autoimmun.
2000;
15
139-143
-
90
Frances C, Papo T, Wechsler B et al.
Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients.
Medicine (Baltimore).
1999;
78
209-219
-
91
Khamashta M A, Cuadrado M J, Mujic F et al.
The management of thrombosis in the antiphospholipid-antibody syndrome.
N Engl J Med.
1995;
332
993-997
-
92
Kurth T.
The association of migraine with ischemic stroke.
Curr Neurol Neurosci Rep.
2010;
10
133-139
-
93
Kurth T, Schurks M, Logroscino G et al.
Migraine frequency and risk of cardiovascular disease in women.
Neurology.
2009;
73
581-588
-
94
Kurth T, Tzourio C.
Migraine and cerebral infarct-like lesions on MRI: an observation, not a disease.
JAMA.
2009;
301
2594-2595
-
95 Savitz S I, Caplan L R. Migraine and Migraine-like conditions.. In: Caplan L R Uncommon causes of stroke.. Cambridge: Cambridge Medicine; 2008
-
96
Beda R D, Gill Jr E A.
Patent foramen ovale: does it play a role in the pathophysiology of migraine headache?.
Cardiol Clin.
2005;
23
91-96
-
97
Joutel A, Corpechot C, Ducros A et al.
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia.
Nature.
1996;
383
707-710
-
98
Dichgans M, Mayer M, Uttner I et al.
The phenotypic spectrum of CADASIL: clinical findings in 102 cases.
Ann Neurol.
1998;
44
731-739
-
99
Dichgans M, Filippi M, Bruning R et al.
Quantitative MRI in CADASIL: correlation with disability and cognitive performance.
Neurology.
1999;
52
1361-1367
-
100
Dichgans M, Holtmannspotter M, Herzog J et al.
Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study.
Stroke.
2002;
33
67-71
-
101
Mikol J, Henin D, Baudrimont M et al.
[Atypical CADASIL phenotypes and pathological findings in two new French families].
Rev Neurol (Paris).
2001;
157
655-667
-
102
Robinson W, Galetta S L, McCluskey L et al.
Retinal findings in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil).
Surv Ophthalmol.
2001;
45
445-448
-
103
Joutel A, Corpechot C, Ducros A et al.
Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia.
Ann N Y Acad Sci.
1997;
826
213-217
-
104
Joutel A, Favrole P, Labauge P et al.
Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis.
Lancet.
2001;
358
2049-2051
-
105
Dichgans M, Petersen D.
Angiographic complications in CADASIL.
Lancet.
1997;
349
776-777
-
106
Koga Y, Povalko N, Nishioka J et al.
MELAS and L-arginine therapy: pathophysiology of stroke-like episodes.
Ann N Y Acad Sci.
2010;
1201
104-110
-
107
Majamaa K, Turkka J, Karppa M et al.
The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct.
Neurology.
1997;
49
1331-1334
-
108
Sue C M, Crimmins D S, Soo Y S et al.
Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis.
J Neurol Neurosurg Psychiatry.
1998;
65
233-240
-
109
Sue C M, Quigley A, Katsabanis S et al.
Detection of MELAS A3243G point mutation in muscle, blood and hair follicles.
J Neurol Sci.
1998;
161
36-39
-
110
Wozniak M A, Kittner S J, Tuhrim S et al.
Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke.
Stroke.
2010;
41
78-81
-
111
Topaloglu A K, Ashley G A, Tong B et al.
Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.
Mol Med.
1999;
5
806-811
-
112
Desnick R J, Wasserstein M P.
Fabry disease: clinical features and recent advances in enzyme replacement therapy.
Adv Nephrol Necker Hosp.
2001;
31
317-339
-
113
Spada M, Pagliardini S, Yasuda M et al.
High incidence of later-onset fabry disease revealed by newborn screening.
Am J Hum Genet.
2006;
79
31-40
-
114
Hoffmann B, Beck M, Rolfs A et al.
[Fabry disease – complex clinical picture, simple diagnosis procedure, causal treatment].
Dtsch Med Wochenschr.
2008;
133
1965-1972; quiz 1973–1974
-
115
Rolfs A, Bottcher T, Zschiesche M et al.
Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.
Lancet.
2005;
366
1794-1796
-
116
Crutchfield K E, Patronas N J, Dambrosia J M et al.
Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.
Neurology.
1998;
50
1746-1749
-
117
Mitsias P, Levine S R.
Cerebrovascular complications of Fabry’s disease.
Ann Neurol.
1996;
40
8-17
-
118
Mehta A, Beck M, Eyskens F et al.
Fabry disease: a review of current management strategies.
QJM.
2010;
103
641-659
-
119
Eng C M, Guffon N, Wilcox W R et al.
Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease.
N Engl J Med.
2001;
345
9-16
-
120
Ginsberg L, Manara R, Valentine A R et al.
Magnetic resonance imaging changes in Fabry disease.
Acta Paediatr Suppl.
2006;
95
57-62
-
121
Fellgiebel A, Muller M J, Ginsberg L.
CNS manifestations of Fabry’s disease.
Lancet Neurol.
2006;
5
791-795
-
122
Kurth T, Kase C S, Berger K et al.
Smoking and risk of hemorrhagic stroke in women.
Stroke.
2003;
34
2792-2795
-
123
Kurth T, Kase C S, Berger K et al.
Smoking and the risk of hemorrhagic stroke in men.
Stroke.
2003;
34
1151-1155
-
124
Reynolds K, Lewis B, Nolen J D et al.
Alcohol consumption and risk of stroke: a meta-analysis.
JAMA.
2003;
289
579-588
-
125
Caplan L R, Hier D B, Banks G.
Current concepts of cerebrovascular disease – stroke: stroke and drug abuse.
Stroke.
1982;
13
869-872
-
126 Brust J CM. Stroke and Substance Abuse.. In: Caplan L Uncommon Causes of Stroke.. Cambridge: Cambridge Medicine; 2008
-
127
Miyakis S, Lockshin M D, Atsumi T et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost.
2006;
4
295-306
-
128
Hughes G R.
Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.
Br Med J (Clin Res Ed).
1983;
287
1088-1089
-
129
Vila P, Hernandez M C, Lopez-Fernandez M F et al.
Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects.
Thromb Haemost.
1994;
72
209-213
-
130
Janardhan V, Wolf P A, Kase C S et al.
Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study.
Stroke.
2004;
35
736-741
-
131
Rafuse P E, Canny C L.
Initial identification of antinuclear-antibody-negative systemic lupus erythematosus on ophthalmic examination: a case report, with a discussion of the ocular significance of anticardiolipin (antiphospholipid) antibodies.
Can J Ophthalmol.
1992;
27
189-193
-
132
Crowther M A, Ginsberg J S, Julian J et al.
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
N Engl J Med.
2003;
349
1133-1138
-
133
Levine S R, Brey R L, Tilley B C et al.
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.
JAMA.
2004;
291
576-584
-
134 Raupp M. Juvenile Schlaganfälle und deren Veränderung über die Zeit – Dissertation. Freiburg im Breisgau; 2006
-
135
Jacobs B S, Boden-Albala B, Lin I F et al.
Stroke in the young in the northern Manhattan stroke study.
Stroke.
2002;
33
2789-2793
-
136
Chant H, McCollum C.
Stroke in young adults: the role of paradoxical embolism.
Thromb Haemost.
2001;
85
22-29
-
137
Hagen P T, Scholz D G, Edwards W D.
Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.
Mayo Clin Proc.
1984;
59
17-20
-
138
Jones E F, Calafiore P, Donnan G A et al.
Evidence that patent foramen ovale is not a risk factor for cerebral ischemia in the elderly.
Am J Cardiol.
1994;
74
596-599
-
139
Klotzsch C, Janssen G, Berlit P.
Transesophageal echocardiography and contrast-TCD in the detection of a patent foramen ovale: experiences with 111 patients.
Neurology.
1994;
44
1603-1606
-
140
Bendixen B H, Posner J, Lango R.
Stroke in young adults and children.
Curr Neurol Neurosci Rep.
2001;
1
54-66
-
141
Pezzini A, Del Zotto E, Magoni M et al.
Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale.
Stroke.
2003;
34
28-33
-
142
Cramer S C, Rordorf G, Maki J H et al.
Increased pelvic vein thrombi in cryptogenic stroke: results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study.
Stroke.
2004;
35
46-50
-
143
Leon L, Giannoukas A D, Dodd D et al.
Clinical significance of superficial vein thrombosis.
Eur J Vasc Endovasc Surg.
2005;
29
10-17
-
144
Unno N, Mitsuoka H, Uchiyama T et al.
Superficial thrombophlebitis of the lower limbs in patients with varicose veins.
Surg Today.
2002;
32
397-401
-
145
Mohr J P, Thompson J L, Lazar R M et al.
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
N Engl J Med.
2001;
345
1444-1451
-
146
Homma S, Di Tullio M R, Sacco R L et al.
Characteristics of patent foramen ovale associated with cryptogenic stroke. A biplane transesophageal echocardiographic study.
Stroke.
1994;
25
582-586
-
147
McGaw D, Harper R.
Patent foramen ovale and cryptogenic cerebral infarction.
Intern Med J.
2001;
31
42-47
-
148
Wu L A, Malouf J F, Dearani J A et al.
Patent foramen ovale in cryptogenic stroke: current understanding and management options.
Arch Intern Med.
2004;
164
950-956
-
149 Berlit P. Klinische Neurologie. 2. aktualisierte Auflage. Heidelberg: Springer Verlag; 2005
Dr. med. Markus Krämer
Klinik für Neurologie mit klinischer Neurophysiologie
Alfried-Krupp-Krankenhaus
Alfried-Krupp-Str. 21
45117 Essen
Email: Markus.kraemer@krupp-krankenhaus.de
